Companies in #Oncology

AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases, including pyruvate kinase (PK) activation and other cellular metabolism targets. The company markets PYRUKYND® (mitapivat) for hemolytic anemia in adults with PK deficiency and is exploring additional indications in thalassemia and sickle cell disease.

Ascletis Pharma is a China-based clinical-stage biopharmaceutical company developing small-molecule and peptide therapeutics for viral diseases, metabolic diseases (including obesity), and oncology. Its lead metabolic candidate ASC36_35 FDC targets GLP-1/GIP agonism.

Avenda Health is a ai-enabled medical devices company. See today's news for the latest developments.

Bayer (ETR: BAYN) is a diversified life sciences company headquartered in Leverkusen, Germany.

BeOne Medicines is a global oncology company that discovers and develops innovative medicines intended to improve the lives of patients worldwide. The company markets BRUKINSA (zanubrutinib), a BTK inhibitor approved for B-cell malignancies.

Precision molecular diagnostics company (NASDAQ: BLLN) that quantifies biology at the single-molecule level to detect and measure DNA molecules. Its molecular counting platform underpins UNITY Complete, a non-invasive prenatal screen assessing fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw, and the Northstar liquid biopsy franchise: Northstar Select reports tumor mutations from blood, while Northstar Response is a methylation-based assay quantifying cancer burden in real time without a tissue biopsy. Incorporated in 2016 and publicly listed in November 2025, the company grew revenue more than 60% year over year in Q2 2026.

Beijing-headquartered global biotechnology company (SSE: 688796, HKEX: 02315) providing integrated antibody drug development solutions through proprietary gene-editing platforms and RenMab/RenNano antibody discovery engines.

BioNTech is a public biotechnology company developing mRNA-based medicines, cancer immunotherapies, infectious-disease vaccines, and antibody-based oncology programs.

Clinical-stage biotech developing oncology therapies for non-small cell lung cancer, with a lead Tagrisso-chasing EGFR-targeted program.

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Global mid-sized Contract Research Organization (CRO) operating in 23 countries, providing patient-centric clinical trial solutions for biopharma innovators across oncology, rare disease, and cell & gene therapy programs.

Caris Life Sciences is a leading patient-centric next-generation AI TechBio company and precision medicine pioneer. The company operates the Caris Assure and Caris Discovery platforms for molecular profiling of cancer patients, enabling oncologists to match patients to targeted therapies and clinical trials.

Clinical-stage biopharmaceutical company (NASDAQ: CNTX) advancing medicines for solid tumors, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody. In August 2026 the company discontinued its bispecific program to extend its cash runway into 2027.

Elevar Therapeutics is a private oncology-focused biopharmaceutical company developing and commercializing cancer therapies, including programs in liver cancer and other solid tumors.

Eli Lilly and Company is a major global pharmaceutical company with a broad portfolio spanning diabetes/obesity, oncology, neuroscience, immunology, and rare diseases. Its GLP-1 franchise (Mounjaro/tirzepatide, Zepbound) and the oral GLP-1 candidate orforglipron are reshaping obesity care. Lilly has been the most aggressive large-pharma dealmaker of the past decade, completing more biotech buyouts than any other top-12 pharma by revenue, with 10 acquisitions in 2026 alone accounting for roughly half of pharma's total M&A capacity (~$25B+ committed).

Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.

Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Gilead Sciences (NASDAQ: GILD) is a Foster City, California-based biopharmaceutical company with leadership in HIV (Biktarvy, Descovy), viral hepatitis (Sovaldi, Harvoni, Epclusa), and a growing oncology franchise (Trodelvy, Yescarta, Tecartus).

Services: Pharmaceutical medicines, vaccines, consumer healthcare; specialty medicines in HIV, oncology, respiratory; vaccines for hepatitis, HPV, meningitis.

Hansoh Pharmaceutical Group is a China-based biopharmaceutical company with marketed products and development programs across oncology, central nervous system disorders, anti-infectives, metabolic disease, and autoimmune disease.

Huyabio International is a clinical-stage biopharmaceutical company developing novel small molecule oncology therapeutics. Lead program HBI-8000 (tucidinostat) is an HDAC inhibitor that has demonstrated Phase 3 success in melanoma and is approved in China for multiple oncology indications.

Incyte is a oncology / inflammation company. See today's news for the latest developments.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

Medtech company developing NIO Laser Imaging System, using stimulated Raman histology for intraoperative fresh tissue imaging, plus AI-based image analysis for cancer detection.

Commercial-stage biopharmaceutical company (NASDAQ: IOVA) developing and commercializing autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead product Amtagvi (lifileucel) is an individualized T cell therapy approved for previously treated advanced or unresectable or metastatic melanoma, marketed alongside Proleukin (interleukin-2). The pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma, with next-generation programs including LN-145, IOV-2001, IOV-4001, and IOV-3001. Q2 2026 product revenue of $99.3 million (up from $59 million a year earlier) powered a roughly 43% single-day gain and a new 52-week high in August 2026.

Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.

Jazz Pharmaceuticals is a global biopharmaceutical company focused on neuroscience and oncology, with a commercial portfolio that includes Xywav (low-sodium oxybate), Epidiolex (cannabidiol), and Zepzelca (lurbinectedin). The company markets Zepzelca in the U.S. under license from PharmaMar and is facing renewed questions about the drug's accelerated approval in small cell lung cancer after a confirmatory Phase 3 trial failed to meet its primary endpoint.

Kelun-Biotech (Sichuan Kelun-Biotech Biopharmaceutical) is a biologics / adc company. See today's news for the latest developments.

Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for common chronic diseases of high unmet need, including Type 1 diabetes, obesity, oncology, and rare diseases. Unlike most AAV gene therapy companies that focus on rare diseases with small patient populations, Kriya's strategic differentiation is targeting chronic conditions with much larger patient populations. Kriya operates its own in-house, large-scale GMP manufacturing facilities for gene therapy at its Research Triangle Park (Durham, North Carolina) headquarters — a notable strategic departure from the typical gene therapy CDMO-out-source model. The company was founded in 2019 by Shankar Ramaswamy, M.D. (former senior partner at McKinsey and former CEO of Axovant) and has raised over $600M in venture funding. Kriya was selected in June 2026 for the FDA PreCheck Pilot Program for its Durham, NC manufacturing facility.

Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical and biotechnology company under the Kirin Holdings group, focused on developing innovative antibody-based drugs for cancer, kidney disease, immune system diseases, and rare diseases. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Kyowa Kirin is the Japan-based parent of Kyowa Kirin, Inc. (the US subsidiary), and operates as a research-driven biopharma with multiple approved biologics including poteligeo (mogamulizumab, for cutaneous T-cell lymphoma) and Crysvita (burosumab, for X-linked hypophosphatemia). The company announced a $530M biologics manufacturing facility in Sanford, North Carolina in June 2024 — its first US manufacturing site — which was selected in June 2026 for the FDA PreCheck Pilot Program. Kyowa Kirin's US subsidiary (KKNA) operates the Sanford facility and supports the company's clinical and commercial biologics pipeline including rocatinlimab for atopic dermatitis.

Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.

Lunai Bioworks (NASDAQ: LNAI), formerly Renovaro Inc. (renamed August 2025), is an AI-driven precision medicine and biodefense company headquartered in Los Angeles. The company operates through three segments — RENB (cell therapy vaccines), BioSymetrics (AI drug discovery), and RENC (CNS) — developing genetically modified allogeneic dendritic cell therapeutic vaccines including RENB-DC11 for solid tumors (primarily pancreatic) and RENB-DC20 for breast cancer, plus an AI multi-omics platform for early cancer detection and recurrence monitoring. In May 2026 Lunai completed a $20M preferred issuance to acquire CNS delivery and neurotherapeutic IP, and in July 2026 it launched a foundation-funded Parkinson's and rare epilepsy AI discovery collaboration with BrainStorm Therapeutics. The company is also pursuing federal biodefense contracts. Since May 2026 it has pursued a naked-short-selling fraud suit under Regulation SHO and RICO, filing a First Amended Complaint on August 4, 2026 naming ten defendants including three FINRA-registered broker-dealers.

Myricx Bio is a UK-based biotech developing a pipeline of antibody-drug conjugates (ADCs) for cancer using its proprietary N-myristoyltransferase inhibitor (NMTi) payload chemistry. The company raised a GBP 90M Series A and is being acquired by Novartis for up to $1.5B.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Orca Bio is a clinical-stage cell therapy company developing high-precision, allogeneic cell therapies for cancer and autoimmune diseases.

Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.

AI-enabled precision oncology biotech that uses multimodal patient data, biological modeling, and machine learning to identify Phase 1 cancer drugs for specific patient subgroups, partnering with pharma for clinical trial design and drug repositioning.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

Phanes Therapeutics is a clinical-stage biotechnology company focused on innovative drug discovery and development in oncology. Recently expanded its clinical trial collaboration with Merck to evaluate spevatamig in combination with KEYTRUDA for biliary tract cancer.

Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers and other difficult-to-treat tumors.

Sail Biomedicines is a Flagship Pioneering-backed in vivo CAR-T biotech engineering mRNA-encoded therapeutics to treat autoimmune disease and cancer. The company is developing programmable medicines that instruct the body to produce its own therapeutic proteins inside target cells.

Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead product, apitegromab, is being developed for spinal muscular atrophy (SMA).

Scribe Therapeutics is a clinical-stage gene editing company developing next-generation CRISPR-based therapies for serious genetic diseases.

Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA splicing modulators using its proprietary SkySTAR platform, with programs in neurology, oncology, autoimmune, and fibrotic diseases.

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Its platform collects and analyzes clinical and molecular data to enable physicians and researchers to make data-driven decisions in oncology, cardiology, and other disease areas.

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).

AI-driven drug discovery company applying generative models and machine learning to small molecule and biologics design.

Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.